Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 1/20 | 0.33 |
| ▸ | BTK | Q06187 | 1/20 | 0.33 |
| ▸ | CASP3 | P42574 | 1/20 | 0.32 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.32 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.32 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.32 |
| ▸ | CTSS | P25774 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.31 |
| ▸ | ITGB7 | P26010 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA4 | P22748 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3222983 | 0.84 | ATM (0.39) | JAK3BTKCASP3SENP8SENP7 | |
| SCHEMBL2103666 | 0.78 | MEN1 (0.37) | JAK3BTKCTSSCTSKITGA4 | |
| SCHEMBL13162785 | 0.78 | MEN1 (0.37) | JAK3BTKCTSSCTSKITGA4 | |
| SCHEMBL10215115 | 0.77 | ITGA4 (0.39) | JAK3BTKCTSSCTSKGPR119 | |
| SCHEMBL2617430 | 0.77 | ITGA4 (0.39) | JAK3BTKCTSSCTSKGPR119 | |
| SCHEMBL2103672 | 0.76 | ITGA4 (0.39) | JAK3BTKCTSSCTSKITGA4 | |
| SCHEMBL2105674 | 0.75 | ALDH1A1 (0.46) | — | |
| SCHEMBL4794108 | 0.74 | ITGA4 (0.34) | JAK3BTKCTSSCTSKITGA4 | |
| SCHEMBL2631416 | 0.74 | ATM (0.38) | JAK3BTKCTSSCTSKITGA4 | |
| SCHEMBL2617422 | 0.72 | ATM (0.38) | JAK3BTKCTSSCTSKITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163919-B2 | Imidazopyridinyl benzamide mitotic kinesin inhibitors | CYTOKINETICS, INCORPORATED (US) | 2012-04-24 | — | — | US | disclosed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | JAK3 3389/4885BTK 4368/4885CASP3 2838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.